search
Back to results

A Study of rTMS Personalized Precision Treatment of Post-stroke Depression

Primary Purpose

Post-stroke Depression

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
"personalized" rTMS+drug treatment
Traditional rTMS +drug treatment
Sponsored by
Zhujiang Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post-stroke Depression focused on measuring Repetitive transcranial magnetic stimulation

Eligibility Criteria

25 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

(1) First-time ischemic stroke with clinical and MRI or CT findings of basal ganglia stroke (ICD-10-CM code 293.83[F06.32]) (3) Right-handedness (4)Clear consciousness (5)Aged 25-75 years with a recent (less than 24 months) ischemic stroke;

Exclusion Criteria

  1. Aphasia or severe cognitive impairment, severe hearing impairment;
  2. Contraindications of MRI scan and rTMS treatment such as pacemaker implantation; (3)Depression caused by psychoactive substances and non addictive substances;(4)Prior history of depressive disorders or major trauma within 1 year, severe depression or any other severe mental disorders;

(5)Pregnant or breast-feeding women; (6)Refusal to sign informed consent of this study

Sites / Locations

  • Zhujiang hospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

"personalized" rTMS+drug treatment

Traditional rTMS +drug treatment

Arm Description

Received "personalized" rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks

Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks

Outcomes

Primary Outcome Measures

response rate
Compare the HAMD-24 scores from baseline to the end of the treatment.the response to treatment is defined as at least a 30% reduction of the HAMD-24 total score with a final HAMD-24 score. The score decreased by more than 50% for the treatment of good results.The response rate is defined as the percentage of number of response.

Secondary Outcome Measures

Neuropsychological tests results of SAS
Get the change of the result of self-rating anxiety scale (SAS) by Comparing the change of SAS scores from baseline to the end of the treatment in each group.
Neuropsychological tests results of ADLs
Get the change of the result of Activities of Daily Living Scale (ADLs) by Comparing the change of ADLs scores from baseline to the end of the treatment in each group.

Full Information

First Posted
July 18, 2017
Last Updated
March 15, 2018
Sponsor
Zhujiang Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03256305
Brief Title
A Study of rTMS Personalized Precision Treatment of Post-stroke Depression
Official Title
A Clinical Control Study of rTMS Personalized Precision Treatment of Post-stroke Depression Based on Mechanism of Emotional Circuit Imbalance
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Unknown status
Study Start Date
December 2016 (undefined)
Primary Completion Date
October 2018 (Anticipated)
Study Completion Date
October 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zhujiang Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a multicenter, randomized trial aims to reveal the efficacy and safety of Repetitive transcranial magnetic stimulation (rTMS) individualized therapy based on the 'emotional loop destabilization' mechanism of PSD .One hundred and twenty participants will be recruited from three centers and randomized with a 1:1 ratio to receive "Personalized" rTMS treatment or traditional rTMS treatment in addition to routine antidepressant treatments.The data of neuropsychological tests and MRI will be collected at 0, 2,4 and 8 weeks after the commencement of the treatment.
Detailed Description
This is a multicenter, randomized trial aims to reveal the efficacy and safety of rTMS individualized therapy based on the 'emotional loop destabilization' mechanism of PSD .One hundred and twenty participants will be recruited from three centers and randomized with a 1:1 ratio to receive "Personalized" rTMS treatment or traditional rTMS treatment in addition to routine antidepressant treatments. Based on inclusion and exclusion criteria, after stroke depression (post-stroke depression, PSD) cases were collected and randomized into two groups: "individualized" rTMS+ drug treatment group and traditional rTMS plus traditional drug treatment group. The main indicators were the effective rate of treatment.Based on inclusion and exclusion criteria, after stroke depression (post-stroke depression, PSD) cases were collected and randomized into two groups: "individualized" rTMS+ drug treatment group and traditional rTMS plus traditional drug treatment group. The main indicators were the effective rate of treatment. The primary outcome is the measurement of 24-item Hamilton Depression Rating Scale (HAMD-24) scores, the secondary outcomes include National Institutes of Health Stroke Scale (NIHSS), Activities of Daily Living Scale (ADLs),self-rating anxiety scale(SAS). The record of the adverse reactions and sequelae during treatment and follow-up, with a view to providing a better clinical method for the treatment of PSD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-stroke Depression
Keywords
Repetitive transcranial magnetic stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Care Provider, Investigator, Outcomes Assessor
Masking
Participant
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
"personalized" rTMS+drug treatment
Arm Type
Experimental
Arm Description
Received "personalized" rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
Arm Title
Traditional rTMS +drug treatment
Arm Type
Active Comparator
Arm Description
Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
Intervention Type
Device
Intervention Name(s)
"personalized" rTMS+drug treatment
Other Intervention Name(s)
P rTMS
Intervention Description
High frequency(10HZ)stimulation of brain regions corresponding to lesion, low-frequency (1HZ)stimulation of the contralateral brain, intensity=90%MT(motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
Intervention Type
Device
Intervention Name(s)
Traditional rTMS +drug treatment
Other Intervention Name(s)
T rTMS
Intervention Description
Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
Primary Outcome Measure Information:
Title
response rate
Description
Compare the HAMD-24 scores from baseline to the end of the treatment.the response to treatment is defined as at least a 30% reduction of the HAMD-24 total score with a final HAMD-24 score. The score decreased by more than 50% for the treatment of good results.The response rate is defined as the percentage of number of response.
Time Frame
Before treatment.1week, 2weeks, 4weeks, 8weeks after treatment
Secondary Outcome Measure Information:
Title
Neuropsychological tests results of SAS
Description
Get the change of the result of self-rating anxiety scale (SAS) by Comparing the change of SAS scores from baseline to the end of the treatment in each group.
Time Frame
Before treatment.1week, 2weeks, 4weeks, 8weeks after treatment
Title
Neuropsychological tests results of ADLs
Description
Get the change of the result of Activities of Daily Living Scale (ADLs) by Comparing the change of ADLs scores from baseline to the end of the treatment in each group.
Time Frame
Before treatment.1week, 2weeks, 4weeks, 8weeks after treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria (1) First-time ischemic stroke with clinical and MRI or CT findings of basal ganglia stroke (ICD-10-CM code 293.83[F06.32]) (3) Right-handedness (4)Clear consciousness (5)Aged 25-75 years with a recent (less than 24 months) ischemic stroke; Exclusion Criteria Aphasia or severe cognitive impairment, severe hearing impairment; Contraindications of MRI scan and rTMS treatment such as pacemaker implantation; (3)Depression caused by psychoactive substances and non addictive substances;(4)Prior history of depressive disorders or major trauma within 1 year, severe depression or any other severe mental disorders; (5)Pregnant or breast-feeding women; (6)Refusal to sign informed consent of this study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Wen Wu, M.D
Phone
+86-020-62783189
Email
wuwen66@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wen Wu, M.D.
Organizational Affiliation
Zhujiang Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Zhujiang hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wen Wu, M.D.
Phone
+86-020-62783189
Email
wuwen66@163.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25269762
Citation
Broomfield NM, Quinn TJ, Abdul-Rahim AH, Walters MR, Evans JJ. Depression and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from a regional stroke registry. BMC Neurol. 2014 Oct 1;14:198. doi: 10.1186/s12883-014-0198-8.
Results Reference
background
PubMed Identifier
26398527
Citation
Concerto C, Lanza G, Cantone M, Ferri R, Pennisi G, Bella R, Aguglia E. Repetitive transcranial magnetic stimulation in patients with drug-resistant major depression: A six-month clinical follow-up study. Int J Psychiatry Clin Pract. 2015;19(4):252-8. doi: 10.3109/13651501.2015.1084329. Epub 2015 Sep 23.
Results Reference
background
PubMed Identifier
23329161
Citation
Damasio A, Carvalho GB. The nature of feelings: evolutionary and neurobiological origins. Nat Rev Neurosci. 2013 Feb;14(2):143-52. doi: 10.1038/nrn3403.
Results Reference
background
PubMed Identifier
24713406
Citation
De Ryck A, Brouns R, Geurden M, Elseviers M, De Deyn PP, Engelborghs S. Risk factors for poststroke depression: identification of inconsistencies based on a systematic review. J Geriatr Psychiatry Neurol. 2014 Sep;27(3):147-58. doi: 10.1177/0891988714527514. Epub 2014 Apr 7.
Results Reference
background
PubMed Identifier
25451004
Citation
De Ryck A, Fransen E, Brouns R, Geurden M, Peij D, Marien P, De Deyn PP, Engelborghs S. Poststroke depression and its multifactorial nature: results from a prospective longitudinal study. J Neurol Sci. 2014 Dec 15;347(1-2):159-66. doi: 10.1016/j.jns.2014.09.038. Epub 2014 Oct 2.
Results Reference
background
PubMed Identifier
24670433
Citation
Dwyer Hollender K. Screening, diagnosis, and treatment of post-stroke depression. J Neurosci Nurs. 2014 Jun;46(3):135-41. doi: 10.1097/JNN.0000000000000047.
Results Reference
background
PubMed Identifier
25655394
Citation
Eriksen S, Gay CL, Lerdal A. Acute phase factors associated with the course of depression during the first 18 months after first-ever stroke. Disabil Rehabil. 2016;38(1):30-5. doi: 10.3109/09638288.2015.1009181. Epub 2015 Feb 6.
Results Reference
background
PubMed Identifier
26219630
Citation
Jastorff J, Huang YA, Giese MA, Vandenbulcke M. Common neural correlates of emotion perception in humans. Hum Brain Mapp. 2015 Oct;36(10):4184-201. doi: 10.1002/hbm.22910. Epub 2015 Jul 28.
Results Reference
background
PubMed Identifier
24878979
Citation
Li W, Ling S, Yang Y, Hu Z, Davies H, Fang M. Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments. Neuro Endocrinol Lett. 2014;35(2):104-9.
Results Reference
background
PubMed Identifier
14627768
Citation
Narushima K, Kosier JT, Robinson RG. A reappraisal of poststroke depression, intra- and inter-hemispheric lesion location using meta-analysis. J Neuropsychiatry Clin Neurosci. 2003 Fall;15(4):422-30. doi: 10.1176/jnp.15.4.422.
Results Reference
background
PubMed Identifier
26453680
Citation
Riccelli R, Passamonti L, Cerasa A, Nigro S, Cavalli SM, Chiriaco C, Valentino P, Nistico R, Quattrone A. Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients. Mult Scler. 2016 Jul;22(8):1094-105. doi: 10.1177/1352458515606987. Epub 2015 Oct 9.
Results Reference
background
PubMed Identifier
3766786
Citation
Robinson RG, Lipsey JR, Rao K, Price TR. Two-year longitudinal study of post-stroke mood disorders: comparison of acute-onset with delayed-onset depression. Am J Psychiatry. 1986 Oct;143(10):1238-44. doi: 10.1176/ajp.143.10.1238.
Results Reference
background
PubMed Identifier
25457685
Citation
Sun N, Li QJ, Lv DM, Man J, Liu XS, Sun ML. A survey on 465 patients with post-stroke depression in China. Arch Psychiatr Nurs. 2014 Dec;28(6):368-71. doi: 10.1016/j.apnu.2014.08.007. Epub 2014 Sep 3.
Results Reference
background
PubMed Identifier
26743441
Citation
Valiengo L, Casati R, Bolognini N, Lotufo PA, Bensenor IM, Goulart AC, Brunoni AR. Transcranial direct current stimulation for the treatment of post-stroke depression in aphasic patients: a case series. Neurocase. 2016;22(2):225-8. doi: 10.1080/13554794.2015.1130231. Epub 2016 Jan 8.
Results Reference
background
PubMed Identifier
26488345
Citation
Wichowicz HM, Gasecki D, Landowski J, Lass P, Swierkocka M, Wisniewski G, Nyka WN, Wilkowska A. Clinical utility of chosen factors in predicting post-stroke depression: a one year follow-up. Psychiatr Pol. 2015;49(4):683-96. doi: 10.12740/PP/38439. English, Polish.
Results Reference
background
PubMed Identifier
25871495
Citation
Yang S, Hua P, Shang X, Cui Z, Zhong S, Gong G, Humphreys GW. A significant risk factor for poststroke depression: the depression-related subnetwork. J Psychiatry Neurosci. 2015 Jul;40(4):259-68. doi: 10.1503/jpn.140086.
Results Reference
background
PubMed Identifier
26602972
Citation
Zhao Q, Tang Y, Chen S, Lyu Y, Curtin A, Wang J, Sun J, Tong S. Early perceptual anomaly of negative facial expression in depression: An event-related potential study. Neurophysiol Clin. 2015 Dec;45(6):435-43. doi: 10.1016/j.neucli.2015.09.011. Epub 2015 Nov 18.
Results Reference
background
PubMed Identifier
34707489
Citation
Zhang X, Shi Y, Fan T, Wang K, Zhan H, Wu W. Analysis of Correlation Between White Matter Changes and Functional Responses in Post-stroke Depression. Front Aging Neurosci. 2021 Oct 11;13:728622. doi: 10.3389/fnagi.2021.728622. eCollection 2021.
Results Reference
derived

Learn more about this trial

A Study of rTMS Personalized Precision Treatment of Post-stroke Depression

We'll reach out to this number within 24 hrs